Mayne Pharma Group

Mayne Pharma Group R&D per Employee

The R&D Spending per Employee of Mayne Pharma Group (MYX.AX) as of Nov 3, 2026 is 24,409.41 AUD. In the previous year, R&D Spending per Employee was 22,908.24 AUD — a change of 6.55% (higher).

R&D per Employee

24,409.41AUD

YoY

6.55%

Last updated:

R&D Spending per Employee of Mayne Pharma Group is 2026 24,409.41 AUD. R&D Spending per Employee of Mayne Pharma Group was 2025 22,908.24 AUD. It decreases by 6.55% higher compared to the previous year.

The Mayne Pharma Group R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2019
30,358.82 AUD
Jan 1, 2020
25,583.53 AUD
Jan 1, 2021
22,247.06 AUD
Jan 1, 2022
14,361.18 AUD
Jan 1, 2023
18,504.71 AUD
Jan 1, 2024
23,807.06 AUD
Jan 1, 2025
22,908.24 AUD
Jan 1, 2026
24,409.41 AUD
The Mayne Pharma Group R&D per Employee history
YEARR&D per EmployeeYoY
24,409.41AUD+6.55%
22,908.24AUD-3.78%
23,807.06AUD+28.65%
18,504.71AUD+28.85%
14,361.18AUD-35.45%
22,247.06AUD-13.04%
25,583.53AUD-15.73%
30,358.82AUD+109.75%
14,474.12AUD+48.68%
9,735.29AUD-5.22%
10,271.76AUD+56.25%
6,574.12AUD+22.76%
5,355.29AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mayne Pharma Group Stock analysis

What does Mayne Pharma Group do? Mayne Pharma Group Ltd. is a leading company in the field of pharmaceutical development and production with manufacturing facilities in Australia and the USA. The company is headquartered in Sydney, Australia and employs over 1,100 employees worldwide. The history of Mayne Pharma dates back to 1845 when the company was founded as a manufacturer of herbal medicine. Over the years, the company has evolved and focused on the pharmaceutical industry, eventually being renamed Mayne Nickless Ltd in 1981. In 2000, the company established its subsidiary Mayne Pharma, specializing in the development and production of generic drugs. Through the acquisition of other companies, Mayne Pharma has expanded its product range and expanded into the USA in 2007. Mayne Pharma focuses on the production of generics and specialty pharmaceuticals, which are marketed worldwide through a variety of distribution channels. The company invests heavily in research and development to develop new products and improve existing ones. The goal is to continuously expand the offering and increase market presence. Through the expansion of the product portfolio and the exploration of new markets, Mayne Pharma has gained a strong position in the pharmaceutical industry in recent years. Mayne Pharma is divided into three divisions: generics, specialty pharmaceuticals, and beauty products. The generics division includes a wide range of prescription generic drugs marketed in the USA, Australia, Canada, and other countries. The company is able to produce cost-effective medications to provide affordable drugs to patients worldwide. The specialty pharmaceuticals division focuses on medications for the treatment of diseases such as cancer, pain, and cardiovascular diseases. Mayne Pharma aims to improve treatment outcomes for patients in these areas and has a promising product development pipeline that includes many innovative therapy options. The beauty products division offers a wide range of high-quality skincare products sold worldwide. This includes skin creams, lip care products, and sunscreens. This division is growing steadily and offers great potential, as it operates not only in the healthcare sector but also in the beauty market. Mayne Pharma has a wide range of products, ranging from medications for everyday ailments to life-saving specialty preparations. Key products include: - Doryx: An oral antibiotic therapy for the treatment of mild to moderate acne. - Lonsurf: A cancer-fighting medication that extends the survival time of advanced colorectal cancer patients. - Kapanol: A long-acting opioid for pain relief in patients with severe pain. - Tolsura: An easy-to-use medication for the treatment of fungal infections, particularly suitable for patients who have difficulty swallowing tablets. - Zenavod: A topical medication for the treatment of vaginal infections. - Golden Glow Sunscreen: A high-quality sunscreen with SPF 50+ that prevents skin irritation and sunburn. In conclusion, Mayne Pharma is a proven and innovative company that focuses on the development and production of generics and specialty pharmaceuticals. With its extensive product range and business activities in key international markets, Mayne Pharma has an outstanding reputation in the pharmaceutical industry. Mayne Pharma Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mayne Pharma Group stock

R&D Spending per Employee of Mayne Pharma Group is 24,409.41 AUD in 2026.

R&D Spending per Employee of Mayne Pharma Group changed from 22,908.24 AUD to 24,409.41 AUD, representing a 6.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Mayne Pharma Group since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Mayne Pharma Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Mayne Pharma Group

All Key Metrics — Mayne Pharma Group